Board of Directors

David is a partner at Atlas Venture where he has co-founded and led the growth of multiple biotech companies. Since joining Atlas in 2010, David has co-founded and served as chief executive officer of numerous companies including Arteaus Therapeutics (acquired by Eli Lilly) and Annovation Biopharma (acquired by The Medicines Company). He was a founding board member of both Delinia (acquired by Celgene), and Cadent Therapeutics (acquired by Novartis). David is a co-founder and board member of Q32 Bio and Vima Therapeutics, and also sits on the boards of Aerovate Therapeutics, Comanche Biopharma, and TRIANA Biomedicines. He was previously a board director of Surface Oncology (acquired by Coherus) and of Xilio Therapeutics, and a board observer at Day One Biopharmaceuticals. David serves as an advisor to several organizations including Memorial Sloan Kettering Cancer Center’s Technology Development Fund, as well as the American Heart Association’s One Brave Idea. David received an M.D. from Harvard Medical School and a B.A. from Stanford University. He completed his internship and residency training in internal medicine at Massachusetts General Hospital.